Category Archives: – Biotech

Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis

Posted on December 1, 2018 by admin

January 31, 2017- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas | Leave a comment

KIT inhibition by Gleevec (imatinib) for severe asthma

Posted on September 1, 2018 by admin

May 26, 2017- Interviewed by Steven E. Greer, MD Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers

Posted in - Biotech, - NEJM, - Pharma, National Jewish Health, Pulmonology | Leave a comment

Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways

Posted on September 1, 2018 by admin

March 19, 2013- Interviewed by Steven E. Greer, MD The upcoming ASCO meeting will be dominated by numerous presentations relating to new

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Bending the cost curve of cancer care

Posted on February 26, 2018 by admin

May 25, 2011- Since the approval of Genentech’s costly Avastin in 2004, prominent oncologists have warned that

Posted in - Biotech, - Pharma, CMS, Oncology, VCU | Leave a comment

Review of combination immunotherapies seen at ASCO 2016

Posted on January 2, 2018 by admin

June 22, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma,

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

This could be the best interview ever aired on Fox Business

Posted on November 15, 2017 by admin

August 15, 2017- by Steven E. Greer, MD Martin Shkreli was on Fox Business today, and the set seemed familiar. Ironically, I was in this same

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy | Leave a comment

Interview with the CEO of Galena Biopharma about cancer vaccines

Posted on November 5, 2017 by admin

February 8, 2016- Interviewed by Steven E. Greer, MD

Posted in - Biotech, Oncology | Leave a comment

CheckMate 026: Why did Opdivo (nivolumab) fail in NSCLC?

Posted on September 9, 2017 by admin

September 1, 2016- Interviewed by Steven E. Greer, MD In the wake of the news-making failure of CheckMate 026 of Bristol-Myers Squibb’s Opdivo (nivolumab) fail in

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Interview with the CEO of Synthetic Biologics, Jeff Riley

Posted on September 1, 2017 by admin

February 8, 2016- Interviewed by Steven E. Greer, MD

Posted in - Biotech, Gastroenterology and liver, Infectious disease, NIH | Leave a comment

The Biggest Healthcare Stories of 2016

Posted on December 26, 2016 by admin

December 26, 2016- by Steven E. Greer, MD for The Healthcare Channel Policy changes dominated the 2016 year in healthcare news. There were few important new drug

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - The Weekly Summary, CMS, FDA | Leave a comment

Ibrance (palbociclib) to treat advanced breast cancer

Posted on November 1, 2016 by admin

November 28, 2016- Interviewed by Steven E. Greer, MD We interviewed Richard Finn,

Posted in - Biotech, - NEJM, - Pharma, Oncology, UCLA | Leave a comment

The Biggest stories of 2015

Posted on October 20, 2016 by admin

December 31, 2015- by Steven E. Nike Roshe Run Femme Greer, MD 2015 was the year of ISIS. The radical jihadist group started the year with an attack in France,

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - Reviews, books, devices, - The Weekly Summary | Leave a comment

The telomerase inhibitor Imetelstat developed by Geron

Posted on February 5, 2016 by admin

September 9, 2015-

Posted in - Biotech, - NEJM, Oncology | Leave a comment

Are the new PCSK9 cholesterol lowering drugs worth the high cost?

Posted on December 7, 2015 by admin

December 16, 2015- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Opinion, - Pharma, - Policy, Cardiology, CMS, FDA | Leave a comment

Martin Shkreli, CEO of Turing Pharmaceuticals, could be the Bernie Madoff of the drug industry

Posted on September 25, 2015 by admin

September 22, 2015- by Steven E. Greer, MD Making national news today was Martin Shkreli, the baby-faced, greasy-haired, disheveled-looking

Posted in - Biotech, - Pharma, Congress, FDA | Leave a comment

Actavis 1000% drug price hike: a case for healthcare reform

Posted on September 22, 2015 by admin

Update September 21, 2015- The Healthcare Channel was the first to report in 2009 on the business strategy of acquiring cheap generic drugs, cornering the market, then raising

Posted in - Biotech, - Generics, - Opinion, - Policy, CMS, Congress, FDA, Infectious disease | Leave a comment

The PCSK9 LDL drugs do not cut heart risk in half

Posted on March 18, 2015 by admin

March 18, 2015- Op-Ed by Steven E. Greer, MD The American College of Cardiology (ACC) meeting is underway, and the main Late Breaking data

Posted in - Biotech, - Opinion, Cardiac surgery, Cardiology, Primary care medicine | Leave a comment

New therapies for hepatitis C

Posted on November 6, 2013 by admin

November 6, 2013- Interviewed by Steven E. Greer, MD In Part 1, Sammy Saab, MD, MPH, liver disease and GI doctor from UCLA, discusses the standard of care

Posted in - Biotech, - Pharma, Gastroenterology and liver, Infectious disease, UCLA | Leave a comment

Super rapid acting insulin and inhaled insulin

Posted on September 9, 2013 by admin

September 9, 2013- Interviewed by Steven E. Greer, MD Jay Skyler, MD, PhD, Deputy Director of the Diabetes Research Institute at The University

Posted in - Biotech, - Pharma, Diabetes and endocrinology, Univ Miami | Leave a comment

anti-PD1 and anti-PD-L1 drugs treating NSCLC

Posted on March 26, 2013 by admin

March 26, 2013 Interviewed By Steven E. Greer, MD

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment